Recruiting

OviTex Core & OviTex 1S

Sponsor:

Tela Bio Inc

Code:

NCT07070115

Conditions

Hiatal Hernia

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Not accepted

Interventions

OviTex Reinforced Tissue Matrix

Study Details

Brief summary:

This study will evaluate hiatal hernia recurrence rate and post-operative complications following the use of OviTex Core Resorbable or OviTex 1S Resorbable.

Conditions

Hiatal Hernia

Study ID

NCT07070115

Start date

Jul 25, 2025

Status verified date

Feb, 2026

Completion date

Jul 31, 2032

Anticipated

Primary completion date

Dec 31, 2031

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Patient is a candidate for an elective robotic or laparoscopic primary hiatal hernia repair with the use of OviTex Core Resorbable or OviTex 1S Resorbable.
2. Patient is willing and able to voluntarily sign the IRB-approved Informed Consent Form for the study.
3. Patient is at least 22 years old at the time of surgery.
4. Patient is not pregnant and not planning to become pregnant during the duration of the study (5 years).
5. Patient is able and willing to comply with the study requirements including completion of patient questionnaires and clinic evaluations.

Exclusion Criteria (Baseline):

1. Patient has a Body Mass Index (BMI) of ≥ 35.
2. Patient meets the Centers for Disease Control (CDC) Surgical Site Infection (SSI) Wound Classification Class IV (Dirty-Infected) criteria.
3. Patient has a Type I hiatal hernia (defined as only the esophagogastric junction is above the diaphragm).
4. Patient has a life expectancy of less than five years making it unlikely that the subject will successfully achieve five-year follow-up.
5. Patient is a current nicotine user (including smokeless, vaporized, etc.)
6. Patient has a history of illicit drug or alcohol abuse (in the last three years).
7. Patient has an allergy to ovine-derived products or a known sensitivity to polyglycolic acid (PGA).
8. Patient has an allergy to barium.
9. Patient's surgery will include the use of an anti-reflux implantable device (LINX, etc.).
10. Patient's surgery requires the use of an additional mesh device or a pledget for reinforcement.
11. Patient has participated in another gastrointestinal (GI) clinical study within the past 30 days or is currently involved in another clinical study excluding observational and registry studies.
12. Patient had previous surgery at the gastroesophageal junction.
13. Patient had a prior hiatal hernia repair.
14. Patient has an incarcerated hernia that requires emergent intervention.
15. Patient is a prisoner.

Exclusion Criteria (Intra-operative):

1. Patient is unable to receive OviTex Core Resorbable or OviTex 1S Resorbable at time of surgery.
2. Surgery requires the use of an additional mesh device or a pledget for reinforcement.
3. Surgery includes the use of an anti-reflux implantable device (LINX, etc.).
4. Surgery performed as an open procedure.
5. Patient has a condition, which in the Investigator's opinion, may put the patient at increased risk, confound study data, or interfere significantly with the patient's participation in the study.

Study Design

Enrollment

173 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

other: OviTex Reinforced Tissue Matrix

This is a single-arm study. All study subjects will receive OviTex.

Interventions

OviTex Reinforced Tissue Matrix

All study subjects will receive OviTex. All OviTex Reinforced Tissue Matrices are intended for use as a surgical mesh to reinforce or repair soft tissue where weakness exists.

Primary outcome measure

  • Hernia recurrence [ Time Frame: At 24 months ]

Central Contacts and Locations

Central contacts

Locations

University of South Alabama Health

Recruiting

Mobile, Alabama, United States, 36617

Contacts

Principal Investigator:

William O Richards, MD

SurgOne, PC

Recruiting

Denver, Colorado, United States, 80210

Contacts

Principal Investigator:

Ahmed Zihni, MD

University of Kentucky

Recruiting

Lexington, Kentucky, United States, 40536

Contacts

Principal Investigator:

J. Scott Roth, MD

Wake Forest University Health Sciences

Recruiting

Charlotte, North Carolina, United States, 28204

Contacts

Principal Investigator:

Paul Colavita, MD

The University of Texas at Austin - Dell Medical School

Recruiting

Austin, Texas, United States, 78712

Contacts

Principal Investigator:

F.P. Tripp Buckley III, MD, FACS, FAFS

More Information

Sponsor

Tela Bio Inc

Last update posted

Aug 18, 2026

Last verified

Feb, 2026

Keywords

  • hiatal
  • hernia
  • reinforced tissue matrix

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Tela Bio Inc on 2026-08-18.